AddLife Q1 Sales Miss Forecasts Amid Currency Headwinds

Key Q1 Financial Highlights

Swedish life science supplier AddLife reported first-quarter net sales of SEK 2.65 billion, falling short of the average analyst estimate of SEK 2.74 billion. The company’s earnings per share came in at SEK 1.04, with a net income of SEK 128 million for the period.

Performance and Market Factors

AddLife's net sales saw a 2% decline in the quarter. This result was significantly influenced by adverse currency fluctuations, which reduced both sales and EBITA by 4%. The overall sales figure was further impacted by divested operations, which offset positive growth drivers.

Strategic Growth and Profitability

Despite the sales headwinds, AddLife successfully maintained its EBITA margin at a stable 12.5%, with an EBITA totaling SEK 332 million. The company demonstrated underlying strength with 3% organic growth and 2% acquired growth. As part of its expansion strategy, AddLife completed two acquisitions in the UK and Austria during the quarter.

Summary

While external pressures from currency effects led to a sales shortfall, AddLife's stable profitability and continued acquisition strategy underscore its focus on long-term growth. Market observers will monitor the company's ability to navigate currency markets and integrate new business assets in the upcoming quarters.

FAQ

Q: Why did AddLife's Q1 sales miss expectations?
A: Sales missed forecasts primarily due to a 4% negative impact from currency exchange rates and the effect of divested operations, which offset organic and acquired growth.

Q: What were AddLife's key financial results in Q1?
A: AddLife reported net sales of SEK 2.65 billion, an EBITA of SEK 332 million, and maintained a stable EBITA margin of 12.5%.

Source: Investing.com